• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Radioisotope production heats up

Article

MDS Nordion has begun making commercial quantities of rhenium 186 (Re-186) and high-specific-activity lutetium 177 (Lu-177). Demand is growing for these radioisotopes for use in research aimed at developing new cancer therapies. Lu-177, a low-energy beta

MDS Nordion has begun making commercial quantities of rhenium 186 (Re-186) and high-specific-activity lutetium 177 (Lu-177). Demand is growing for these radioisotopes for use in research aimed at developing new cancer therapies. Lu-177, a low-energy beta emitter, shows promise against small tumors. It has a relatively long 6.65-day half-life, which allows more sophisticated procedures to be used for its purification and synthesis. The long half-life also makes Lu-177 easier to combine with biologically active compounds. Re-186 is being investigated for a range of radiotherapeutic applications. It is currently being used for pain palliation from cancerous metastases in bones. Both Lu-177 and Re-186 emit gamma radiation that enables imaging.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.